326030.KS
SK Biopharmaceuticals Co., Ltd.
KSEKRWEQUITY
Healthcare
DELAYED
Last price
83,700.00
▼ 2,800.00 (3.24%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
84,900.00
Prev close
86,500.00
Day high
85,200.00
Day low
81,900.00
Volume
120.20K
Market cap
$6.55T
P/E (TTM)
—
52W range
73,000.00 – 144,100.00
Day trading desk
Gap from prior close
-1.85%
Prior close 86,500.00
VWAP
82,994.97
+0.85% from price
Relative volume
0.46×
Quiet session
Session range
4.03%
81,900.00 – 85,200.00
Position in range
55%
Mid range
ATR (14D)
3,700.00
4.42% of price
Prior day high
88,600.00
PDH
Prior day low
85,800.00
PDL
Bid / ask spread
—
Quote not published
Session volume
119.24K
Avg 256.86K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.45%
-3.1%
1M
+8.98%
+5.3%
3M
-8.02%
-11.1%
6M
-26.19%
-37.3%
YTD
-32.83%
-45.1%
1Y
-17.54%
-37.5%
3Y
+13.57%
-60.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 326030.KS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
39.29M
Total on file
Fundamentals
Market cap$6.55T
Enterprise value$6.29T
Revenue (TTM)$790.25B
Gross profit$743.51B
EBITDA$284.28B
Net income$348.81B
EPS (TTM)—
Free cash flow$75.88B
Total cash$310.86B
Total debt$49.98B
Book value / share—
Shares outstanding78.31M
Float39.02M
Short % of float—
Dividend yield—
Beta (5Y)0.73
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue7.96
EV / EBITDA22.14
Gross margin94.09%
Operating margin39.39%
Profit margin44.14%
Return on equity44.16%
Return on assets14.43%
Debt / equity5.36
Current ratio2.49
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $706.74B | $547.60B | $354.89B | $246.18B | +29.1% |
| Operating revenue | $706.74B | $547.60B | $354.89B | $246.18B | +29.1% |
| Cost of revenue | $42.90B | $43.10B | $34.08B | $37.77B | -0.5% |
| Gross profit | $663.84B | $504.50B | $320.81B | $208.41B | +31.6% |
| Research & development | $174.34B | $161.27B | $137.13B | $122.82B | +8.1% |
| Selling, general & admin | $146.29B | $114.79B | $101.87B | $112.32B | +27.4% |
| Total operating expense | $459.90B | $408.16B | $358.33B | $339.49B | +12.7% |
| Operating income | $203.94B | $96.34B | -$37.52B | -$131.08B | +111.7% |
| Net interest income | -$606.07M | -$536.32M | $1.04B | $3.04B | -13.0% |
| Pre-tax income | $150.88B | $72.60B | -$43.86B | -$142.47B | +107.8% |
| Tax provision | -$102.37B | -$154.38B | -$8.48B | -$3.04B | +33.7% |
| Net income | $266.95B | $240.74B | -$32.88B | -$139.43B | +10.9% |
| Net income to common | $266.95B | $240.74B | -$32.88B | -$139.43B | +10.9% |
| Basic EPS | 3,409.00 | 3,074.00 | -420.00 | -1,780.00 | +10.9% |
| Diluted EPS | 3,409.00 | 3,074.00 | -420.00 | -1,780.00 | +10.9% |
| EBIT | $158.57B | $83.28B | -$35.58B | -$138.75B | +90.4% |
| EBITDA | $175.52B | $100.71B | -$20.26B | -$125.77B | +74.3% |
| Basic shares | 78.31M | 78.31M | 78.29M | 78.33M | -0.0% |
| Diluted shares | 78.31M | 78.31M | 78.29M | 78.33M | -0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $307.77B | $322.81B | $239.70B | $104.06B | -4.7% |
| Cash & short-term investments | $309.48B | $324.49B | $241.12B | $305.45B | -4.6% |
| Accounts receivable | $228.83B | $173.82B | $111.00B | $63.51B | +31.6% |
| Inventory | $100.24B | $111.68B | $102.53B | $90.92B | -10.2% |
| Total current assets | $683.23B | $651.37B | $488.72B | $487.92B | +4.9% |
| Property, plant & equipment | $60.51B | $43.93B | $47.75B | $20.35B | +37.7% |
| Goodwill & intangibles | $51.21B | $32.53B | $27.02B | $17.18B | +57.4% |
| Total assets | $1.20T | $1.04T | $723.17B | $664.24B | +15.6% |
| Total current liabilities | $295.20B | $396.28B | $241.62B | $163.07B | -25.5% |
| Current debt | $0 | $150.72B | $50.00B | $0 | -100.0% |
| Long-term debt | — | — | $94.48B | $143.72B | — |
| Total debt | $48.92B | $184.48B | $178.05B | $155.90B | -73.5% |
| Total liabilities | $372.04B | $462.83B | $402.22B | $347.68B | -19.6% |
| Retained earnings | -$354.14B | -$621.53B | -$861.56B | -$827.56B | +43.0% |
| Shareholder equity | $813.04B | $546.27B | $283.69B | $316.56B | +48.8% |
| Working capital | $388.03B | $255.10B | $247.10B | $324.85B | +52.1% |
| Net tangible assets | $761.82B | $513.74B | $256.66B | $299.38B | +48.3% |
| Shares issued | 78.31M | 78.31M | 78.31M | 78.31M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $253.25B | $226.97B | -$35.38B | -$139.43B | +11.6% |
| Depreciation & amortisation | $16.95B | $17.43B | $15.32B | $12.98B | -2.8% |
| Stock-based compensation | $3.63B | $7.51B | $3.23B | $60.66M | -51.6% |
| Change in working capital | -$36.28B | -$32.66B | -$75.64B | -$65.66B | -11.1% |
| Operating cash flow | $176.33B | $94.90B | -$94.20B | -$159.92B | +85.8% |
| Capital expenditure | -$29.51B | -$13.42B | -$3.25B | -$5.96B | -119.8% |
| Investing cash flow | -$35.42B | -$10.94B | $225.27B | -$95.71B | -223.7% |
| Financing cash flow | -$156.68B | -$4.50B | $6.62B | $134.91B | -3,383.2% |
| Free cash flow | $146.82B | $81.48B | -$97.45B | -$165.88B | +80.2% |
| End cash position | $307.77B | $322.81B | $239.70B | $104.06B | -4.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $227.89B | $194.36B | $191.73B | $176.28B | $144.38B | +17.2% |
| Operating revenue | $227.89B | $194.36B | $191.73B | $176.28B | $144.38B | +17.2% |
| Cost of revenue | $14.33B | $14.95B | $7.55B | $9.90B | $10.50B | -4.1% |
| Gross profit | $213.55B | $179.41B | $184.18B | $166.37B | $133.88B | +19.0% |
| Research & development | $47.59B | $51.85B | $40.93B | $39.56B | $42.00B | -8.2% |
| Selling, general & admin | $40.94B | $42.15B | $38.76B | $32.17B | $33.20B | -2.9% |
| Total operating expense | $123.79B | $133.13B | $114.07B | $104.49B | $108.21B | -7.0% |
| Operating income | $89.77B | $46.28B | $70.11B | $61.88B | $25.67B | +94.0% |
| Net interest income | $380.91M | $397.10M | $179.24M | -$337.99M | -$844.42M | -4.1% |
| Pre-tax income | $99.98B | $33.76B | $62.11B | $34.68B | $20.34B | +196.1% |
| Tax provision | -$2.76B | -$98.98B | -$9.26B | $5.15B | $714.08M | +97.2% |
| Net income | $105.16B | $136.59B | $74.14B | $32.92B | $23.30B | -23.0% |
| Net income to common | $105.16B | $136.59B | $74.14B | $32.92B | $23.30B | -23.0% |
| Basic EPS | 1,343.00 | — | 947.00 | 420.00 | 298.00 | — |
| Diluted EPS | 1,343.00 | — | 947.00 | 420.00 | 298.00 | — |
| EBIT | $101.28B | $35.08B | $63.81B | $36.81B | $22.88B | +188.7% |
| EBITDA | $105.22B | $39.04B | $67.81B | $41.16B | $27.51B | +169.5% |
| Basic shares | 78.31M | — | 78.31M | 78.31M | 78.20M | — |
| Diluted shares | 78.31M | — | 78.31M | 78.37M | 78.20M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $308.99B | $307.77B | $254.49B | $220.99B | $266.95B | +0.4% |
| Cash & short-term investments | $310.86B | $309.48B | $256.16B | $222.60B | $268.69B | +0.4% |
| Accounts receivable | $294.06B | $228.83B | $230.32B | $181.24B | $174.82B | +28.5% |
| Inventory | $92.98B | $100.24B | $103.97B | $107.93B | $115.33B | -7.2% |
| Total current assets | $776.88B | $683.23B | $642.86B | $576.12B | $606.95B | +13.7% |
| Property, plant & equipment | $59.05B | $60.51B | $57.77B | $58.39B | $57.80B | -2.4% |
| Goodwill & intangibles | $55.44B | $51.21B | $29.72B | $29.30B | $31.33B | +8.2% |
| Total assets | $1.32T | $1.20T | $1.03T | $952.82B | $1.00T | +10.2% |
| Total current liabilities | $312.15B | $295.20B | $264.57B | $263.19B | $330.23B | +5.7% |
| Current debt | $0 | $0 | $390 | $25.00B | $75.00B | — |
| Total debt | $49.98B | $48.92B | $49.37B | $74.99B | $124.66B | +2.2% |
| Total liabilities | $388.37B | $372.04B | $340.50B | $338.75B | $410.56B | +4.4% |
| Retained earnings | -$248.89B | -$354.14B | -$491.08B | -$565.31B | -$597.91B | +29.7% |
| Shareholder equity | $932.05B | $813.04B | $672.80B | $595.24B | $567.53B | +14.6% |
| Working capital | $464.73B | $388.03B | $378.28B | $312.93B | $276.72B | +19.8% |
| Net tangible assets | $876.61B | $761.82B | $643.08B | $565.93B | $536.20B | +15.1% |
| Shares issued | 78.31M | 78.31M | 78.31M | 78.31M | 78.31M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $102.73B | $132.74B | $71.37B | $29.52B | $19.62B | -22.6% |
| Depreciation & amortisation | $3.93B | $3.96B | $4.00B | $4.36B | $4.63B | -0.5% |
| Stock-based compensation | -$5.11B | $3.65B | $1.74B | -$940.11M | -$815.77M | -240.0% |
| Change in working capital | -$96.75B | $43.15B | -$7.39B | -$56.00B | -$16.03B | -324.2% |
| Operating cash flow | $17.92B | $87.00B | $65.41B | -$3.37B | $27.29B | -79.4% |
| Capital expenditure | -$2.94B | -$26.55B | -$1.28B | -$1.21B | -$477.42M | +88.9% |
| Investing cash flow | -$7.06B | -$29.72B | -$1.87B | -$2.32B | -$1.51B | +76.2% |
| Financing cash flow | -$8.21B | -$1.75B | -$26.65B | -$51.55B | -$76.72B | -367.7% |
| Free cash flow | $14.97B | $60.46B | $64.13B | -$4.57B | $26.81B | -75.2% |
| End cash position | $308.99B | $307.77B | $254.49B | $220.99B | $266.95B | +0.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 581.55 | 1,086.00 | +86.7% |
| Mar 2026 | 481.02 | 1,343.00 | +179.2% |
| Dec 2025 | 434.02 | 1,744.00 | +301.8% |
| Sep 2025 | 342.46 | 947.00 | +176.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 594.78 | 1 | $253.90B | +32.4% |
| Next quarter | 118.38 | 1 | $249.00B | +28.1% |
| Current year | 4,256.43 | 10 | $978.45B | +38.5% |
| Next year | 5,238.00 | 11 | $1.15T | +17.8% |
Analyst targets & ownership
Mean target$128,666.66
High target$160,000.00
Low target$74,000.00
Implied upside53.72%
Analyst count12
ConsensusNONE
Strong buy / Buy5 / 5
Hold1
Sell / Strong sell1 / 0
Held by insiders50.17%
Held by institutions12.53%
Institutions holding145
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
86,840.00
-3.62% from price
SMA 20
83,315.00
+0.46% from price
SMA 50
83,734.00
-0.04% from price
SMA 100
90,493.00
-7.51% from price
SMA 200
104,703.00
-20.06% from price
EMA 12
85,095.23
-1.64% from price
EMA 26
84,096.11
-0.47% from price
EMA 50
85,303.58
-1.88% from price
RSI (14)
49.2
Neutral
MACD (12,26,9)
999.13
Hist 258.87
ATR (14)
3,700.00
4.42% of price
Realised vol 30D
43.8%
Annualised
Bollinger upper
91,486.48
20, 2σ
Bollinger lower
75,143.52
20, 2σ
50 / 200 cross
Death
83,734.00 vs 104,703.00
Trend bias
Below 200
-20.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.34
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
43.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-47.0%
Peak to trough
Max drawdown 5Y
-58.7%
Peak to trough
ATR 14
3,700.00
4.42% of price
Beta (reported)
0.73
5Y monthly, from filing
Headlines
Kane voted German footballer of the year
AFP · 10m ago
Asphalt Expert Robert Stewart Explains Asphalt Driveway Installation Preparation in HelloNation
PR Newswire · 12m ago
Is GE Vernova Under $1,000 a Bargain or a Trap? Here's the Honest Answer.
Motley Fool · 13m ago
The Idiot’s Guide to Stocks
24/7 Wall St. · 16m ago
Exclusive: Anthropic's $2 Trillion Valuation Faces a Reality Check—SPCX Offers a Warning, Wall Street Veteran Says
Benzinga Private Markets · 16m ago
Trump made a multimillion-dollar bond bet — and Fed Chair Kevin Warsh could shape the outcome. What investors can learn
Moneywise · 16m ago
DREAMO and DREAMOSIS Bring the Collectible Character Into a New Physical-Digital World
PR Newswire · 16m ago
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection
PR Newswire · 16m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.